At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 342 enrolled
Drug / intervention
Paclitaxel +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Blind, Multinational, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) With Squamous Histology
In Brief
A Phase 3 clinical trial evaluating Paclitaxel, Carboplatin, and 2 other interventions for Lung Cancer (NSCLC). Completed, enrolled 342 participants across 49 sites in 6 countries.
Detailed Summary
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the life of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer (NSCLC)
CountriesChina, Germany, Hungary, Poland, Singapore, South Korea
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionMay 2018
TodayJul 2026
First PostedOct 31, 2014
Enrollment StartOct 13, 2014
Primary CompletionMay 3, 2018
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.7 years ago
Interventions
Paclitaxelbiological
Carboplatinbiological
Ipilimumabbiological
Placeboother
0.9% sodium chloride injection, USP, or 5% dextrose injection